GHealth News – The FDA has approved a new long-acting HIV prevention drug called lenacapavir, branded as Yeztugo, which could significantly reduce new infections. Administered via injection just twice a year, it offers nearly complete protection based on clinical trials. This is a major advancement compared to existing daily pills or bimonthly injections like Apretude (cabotegravir).
Lenacapavir, produced by Gilead Sciences, is already used to treat drug-resistant HIV and costs $42,000 annually, though most patients receive financial assistance or insurance coverage. By contrast, daily pills cost about $1 each, and Apretude costs $24,000 per year.
Despite its potential to transform HIV prevention, experts warn that funding cuts, especially to Medicaid and PEPFAR, may limit global access. Mitchell Warren of AVAC called the drug the most promising prevention tool in over four decades but said recent U.S. policy decisions risk undermining its impact. Advocacy groups emphasize that while daily pills remain available, they are not effective for everyone.